381 related articles for article (PubMed ID: 24308993)
1. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.
Matter MS; Decaens T; Andersen JB; Thorgeirsson SS
J Hepatol; 2014 Apr; 60(4):855-65. PubMed ID: 24308993
[TBL] [Abstract][Full Text] [Related]
2. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
Lu X; Paliogiannis P; Calvisi DF; Chen X
Hepatology; 2021 Jan; 73 Suppl 1(Suppl 1):49-61. PubMed ID: 32394479
[TBL] [Abstract][Full Text] [Related]
3. Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma.
Huynh H; Ng WH; Soo KC
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203186
[TBL] [Abstract][Full Text] [Related]
4. Targeting mTOR for the treatment of B cell malignancies.
Lee JS; Vo TT; Fruman DA
Br J Clin Pharmacol; 2016 Nov; 82(5):1213-1228. PubMed ID: 26805380
[TBL] [Abstract][Full Text] [Related]
5. Targeting the mTOR signaling network for cancer therapy.
Meric-Bernstam F; Gonzalez-Angulo AM
J Clin Oncol; 2009 May; 27(13):2278-87. PubMed ID: 19332717
[TBL] [Abstract][Full Text] [Related]
6. New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma.
Agulnik M
Cancer; 2012 Mar; 118(6):1486-97. PubMed ID: 21837674
[TBL] [Abstract][Full Text] [Related]
7. Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.
Chan SL; Yeo W
World J Gastroenterol; 2014 Mar; 20(12):3135-45. PubMed ID: 24696599
[TBL] [Abstract][Full Text] [Related]
8. Covalent conjugation of AZD8055 with unsaturated fatty acids for the development of mTOR nanoblockers: increasing the therapeutic efficacy of hepatocellular carcinoma treatment.
Chau WK; Lee TKW
EBioMedicine; 2024 May; 103():105113. PubMed ID: 38583261
[No Abstract] [Full Text] [Related]
9. Clinical significance of mechanistic target of rapamycin expression in vessels that encapsulate tumor cluster-positive hepatocellular carcinoma patients who have undergone living donor liver transplantation.
Toshida K; Itoh S; Toshima T; Yoshiya S; Goto R; Mita A; Harada N; Kohashi K; Oda Y; Yoshizumi T
Ann Gastroenterol Surg; 2024 Jan; 8(1):163-171. PubMed ID: 38250695
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin and Alzheimer's disease: Time for a clinical trial?
Kaeberlein M; Galvan V
Sci Transl Med; 2019 Jan; 11(476):. PubMed ID: 30674654
[TBL] [Abstract][Full Text] [Related]
11. Theranostic imaging and multimodal photodynamic therapy and immunotherapy using the mTOR signaling pathway.
Zhou H; Tang D; Yu Y; Zhang L; Wang B; Karges J; Xiao H
Nat Commun; 2023 Sep; 14(1):5350. PubMed ID: 37660174
[TBL] [Abstract][Full Text] [Related]
12. The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside.
Feng Y; Chen X; Cassady K; Zou Z; Yang S; Wang Z; Zhang X
Front Oncol; 2020; 10():611690. PubMed ID: 33489922
[TBL] [Abstract][Full Text] [Related]
13. Targeting ageing with rapamycin and its derivatives in humans: a systematic review.
Lee DJW; Hodzic Kuerec A; Maier AB
Lancet Healthy Longev; 2024 Feb; 5(2):e152-e162. PubMed ID: 38310895
[TBL] [Abstract][Full Text] [Related]
14. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT
JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218
[TBL] [Abstract][Full Text] [Related]
15. Regulation of hypoxia responses by flavin adenine dinucleotide-dependent modulation of HIF-1α protein stability.
Yang SJ; Park YS; Cho JH; Moon B; An HJ; Lee JY; Xie Z; Wang Y; Pocalyko D; Lee DC; Sohn HA; Kang M; Kim JY; Kim E; Park KC; Kim JA; Yeom YI
EMBO J; 2017 Apr; 36(8):1011-1028. PubMed ID: 28279976
[TBL] [Abstract][Full Text] [Related]
16. The Antiproliferative and Colony-suppressive Activities of STAT3 Inhibitors in Human Cancer Cells Is Compromised Under Hypoxic Conditions.
Tian J; Xiao H; Wu R; Cao Y; Li C; Xu R; Pierson CR; Finlay JL; Yang F; Gu N; Lin J
Anticancer Res; 2017 Feb; 37(2):547-553. PubMed ID: 28179300
[TBL] [Abstract][Full Text] [Related]
17. Possible Therapeutic Effects of Ozone Mixture on Hypoxia in Tumor Development.
Luongo M; Brigida AL; Mascolo L; Gaudino G
Anticancer Res; 2017 Feb; 37(2):425-435. PubMed ID: 28179287
[TBL] [Abstract][Full Text] [Related]
18. Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
Llovet JM; Villanueva A; Lachenmayer A; Finn RS
Nat Rev Clin Oncol; 2015 Jul; 12(7):408-24. PubMed ID: 26054909
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy of hepatocellular carcinoma: current and promising.
Kalyan A; Nimeiri H; Kulik L
Clin Liver Dis; 2015 May; 19(2):421-32. PubMed ID: 25921671
[TBL] [Abstract][Full Text] [Related]
20. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Cainap C; Qin S; Huang WT; Chung IJ; Pan H; Cheng Y; Kudo M; Kang YK; Chen PJ; Toh HC; Gorbunova V; Eskens FA; Qian J; McKee MD; Ricker JL; Carlson DM; El-Nowiem S
J Clin Oncol; 2015 Jan; 33(2):172-9. PubMed ID: 25488963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
